Protalix BioTherapeutics Inc. (PLX) 재무 분석
*모든 숫자는 백만 단위입니다.
| 기간 종료일 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|---|
| 기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
| Revenues | 10.20%21.93 | 19.90 | 33.75 | 9.12 | 17.85 |
| Cost Of Revenue | 1.47%7.88 | 7.76 | 4.13 | 4.62 | 8.32 |
1.03%3.08 | 3.11 | 3.05 | 3.53 | - | |
| Selling, General, and Administrative | 1.03%3.08 | 3.11 | 3.05 | 3.53 | - |
| Research and Development | 59.11%6.92 | 4.35 | 5.43 | 5.64 | - |
| Operating Income/Loss | 13.38%4.05 | 4.67 | 21.15 | -4.66 | 2.13 |
| Nonoperating Income/Loss | 205.85%0.58 | 0.19 | -0.01 | -0.12 | 0.11 |
| Income/Loss From Continuing Operations Before Tax | 4.90%4.62 | 4.86 | 21.14 | -4.78 | 2.24 |
| Income Tax Expense/Benefit, Current | 41.70%0.59 | 1.01 | 2.75 | 0.57 | -0.18 |
| Income Tax Expense/Benefit, Deferred | 0.07 | 0.07 | 0.07 | 0.16 | 0.06 |
| Income Tax Expense/Benefit | 38.97%0.66 | 1.08 | 2.82 | 0.73 | -0.12 |
4.87%3.96 | 3.78 | 18.32 | -5.50 | 2.36 | |
| Attributable To Parent | 4.87%3.96 | 3.78 | 18.32 | -5.50 | 2.36 |
| Available To Common Stockholders, Basic | 4.87%3.96 | 3.78 | - | - | 2.36 |
| Basic Average Shares | 0.59%80.46 | 79.99 | 79.85 | - | 79.28 |
| Diluted Average Shares | 1.24%83.59 | 82.56 | 83.05 | - | 80.81 |
| Basic Earnings Per Share | 0.05 | 0.05 | 0.23 | - | 0.03 |
| Diluted Earnings Per Share | 0.05 | 0.05 | 0.22 | - | 0.03 |